Skip to main content

A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies

Trial Status: Active

The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and early clinical activity of single-agent INCB081776 (Part 1) and INCB081776 in combination with INCMGA00012 (Part 2).

Inclusion Criteria

  • Inclusion Criteria: • Male and female participants at least 18 years of age with advanced malignancies who have received or been intolerant to standard therapy: Parts 1A and 2A: - Histologically confirmed advanced or metastatic gastric or GEJ adenocarcinoma, HCC, melanoma, NSCLC, RCC, soft-tissue sarcoma, SCCHN (recurrent or metastatic), TNBC, or urothelial carcinoma. Additional tumor histologies, including MSI-H tumors, may be allowed with approval from the medical monitor. - Measurable disease per RECIST v1.1. Parts 1B and 2B: • Histologic confirmation of the cohort-specific tumor types specified below: Cohort 1 - Advanced or metastatic melanoma Cohort 2 - Advanced or metastatic NSCLC Cohort 3 - Recurrent or metastatic SCCHN Cohort 4 - Advanced or metastatic soft-tissue sarcoma - Cohorts 1-3 must have received 1 prior PD-1/L1 treatment and have experienced PD during or after that treatment and have progressed on other SOC therapy(ies); Cohort 4 must be PD-1/L1 treatment naïve but have progressed on SOC therapy(ies). - Measurable disease per RECIST v1.1. - Must be willing to submit to a fresh baseline tumor biopsy and an on-treatment biopsy between Cycle 2 Day 1 and Cycle 3 Day 1. - Care should be taken to biopsy the same lesion for the baseline and on-treatment samples. If a participant has a solitary target lesion, this should not be biopsied. Part 1C: - Participants with relapsed/refractory AML following standard therapy; acute promyelocytic leukemia (M3) and therapy-related AML are excluded. - FLT3-ITD and IDH1/2 wild-type or mutated are eligible; appropriate targeted therapy for participants with actionable mutations must have been received. Exclusion Criteria: - Laboratory values not within the protocol-defined range. - History of retinal disease as defined in the protocol. - Clinically significant cardiac disease as per protocol-defined criteria. - History or presence of an ECG that, in the investigator's opinion, is clinically meaningful as per protocol-defined criteria. - Untreated brain or central nervous system (CNS) metastases or brain or CNS metastases that have progressed as per protocol-defined criteria. - Active or inactive autoimmune disease or syndrome that has required systemic treatment in the past 2 years or receiving systemic therapy for an autoimmune or inflammatory disease. - Prior Grade 3 or higher immune-related AEs or any ocular toxicity on prior immunotherapy as per protocol-defined criteria. - Receipt of any vitamin K antagonists, systemic corticosteroids, live vaccines, or treatment with any anticancer medications or investigational drugs within the protocol-defined intervals. - Has not recovered to ≤ Grade 1 or baseline from toxic effects of prior therapy and/or complications from prior surgical intervention before starting study treatment. - Active infection requiring systemic therapy. - Evidence of hepatitis B virus or hepatitis C virus infection or risk of reactivation. - Known history of HIV (HIV 1/2 antibodies).


Beth Israel Deaconess Medical Center
Brigham and Women's Hospital
Status: ACTIVE
Dana-Farber Cancer Institute
Status: ACTIVE


University of Pennsylvania / Abramson Cancer Center
Status: ACTIVE
University of Pittsburgh Cancer Institute (UPCI)
Status: ACTIVE


M D Anderson Cancer Center
Status: ACTIVE

Trial Phase Phase I

Trial Type Treatment

Lead Organization
Incyte Corporation

  • Primary ID INCB 81776-101
  • Secondary IDs NCI-2018-01382
  • ID NCT03522142